Fermenters Market By Type (Stainless-Steel Fermenters, Single-Use Fermenters); By Application (Biopharmaceuticals, Food & Beverage, Industrial Biotechnology, Research); By End User (Biotech & Pharma Companies, CDMOs, Food Manufacturers, Academic Institutions); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Fermenters Market: Flexible Biomanufacturing Capacity Reshapes Equipment Demand

The Global Fermenters Market was valued at USD 2.96 billion in 2025 and is projected to reach USD 5.70 billion by 2032, expanding at a CAGR of 9.8% during 2026–2032, according to Strategic Market Research.

 

Fermenters are sealed tanks that grow microorganisms under controlled conditions like temperature, oxygen, and pH, while preventing contamination. They are increasingly used because of rising demand for health foods, medicines, and eco-friendly products. Growth is driven by expanding production of probiotics and functional foods, pharmaceutical manufacturing of drugs and vaccines, and industrial use in biofuels and bioplastics. Advances in automation and control systems are also making fermentation more efficient and cost-effective.

 

Biopharmaceutical Production Remains the Main Revenue Source

Biopharmaceutical applications generated USD 1.3616 billion in 2025, representing 46.0% of the market. Revenue is projected to reach USD 2.85 billion by 2032, expanding at an 11.13% CAGR. Demand comes from monoclonal antibodies, recombinant proteins, vaccines, biosimilars and other biologic products. The U.S. FDA approved 46 novel drugs in 2025, while the European Medicines Agency approved 41 biosimilars. These approvals create demand across process development, clinical manufacturing and commercial production.

 

Stainless Steel Retains Scale Leadership

Stainless-steel fermenters generated USD 2.0128 billion in 2025 and are projected to reach USD 3.4770 billion by 2032, growing at an 8.12% CAGR. End users such as Pfizer, Novozymes, and AB InBev rely on these systems for large-scale biologics, enzyme, and brewing production. These systems remain important in high-volume biologics, brewing, enzymes, antibiotics, amino acids and industrial fermentation. Their advantages include large working volumes, strong mixing, effective heat removal and long operating life.

Single-use fermenters represented 32.0% of 2025 revenue, equal to USD 0.9472 billion. The segment is forecast to reach USD 2.2230 billion by 2032, expanding at a 12.96% CAGR. Disposable product-contact components reduce cleaning requirements and shorten setup times. They are well suited to process development, clinical production, seed trains and multiproduct facilities. Adoption is particularly strong among CDMOs such as Lonza, WuXi Biologics, and Samsung Biologics, as well as biotech firms including Amgen and Moderna, where flexible capacity and rapid product switching are critical.

 

CDMOs Become the Fastest-Growing End-User Group

Biotechnology and pharmaceutical companies accounted for 44.0% of 2025 revenue, or USD 1.3024 billion. The segment is projected to reach USD 2.6790 billion by 2032, growing at a 10.85% CAGR. These companies invest directly in fermentation systems when they require control over strategic biologics, proprietary cell lines or long-term product supply. For example, large biopharma players such as Roche, Pfizer, and Amgen continue to expand in-house biologics manufacturing capacity, driving demand for high-volume stainless-steel fermenters and fully integrated upstream systems.

CDMOs generated USD 0.6808 billion in 2025 and are forecast to reach USD 1.5390 billion by 2032. At a 12.36% CAGR, CDMOs are the fastest-growing end-user segment. Contract manufacturers such as Lonza, WuXi Biologics, and Samsung Biologics require flexible production platforms that can support multiple client molecules and varying batch sizes. Modular and single-use equipment helps them shift capacity between customers with shorter changeover periods.

Academic institutions accounted for 10.0% of the market, or USD 0.2960 billion in 2025. Revenue is projected to reach USD 0.4560 billion by 2032, growing at a 6.37% CAGR. Universities and research centers remain important users of laboratory and pilot-scale fermenters.

 

Food Fermentation Provides Stable Equipment Demand

Food and beverage applications represented 27.0% of 2025 revenue, equal to USD 0.7992 billion. The segment is forecast to reach USD 1.3680 billion by 2032, expanding at a 7.98% CAGR. Demand comes from brewing, dairy cultures, probiotics, yeast, enzymes, organic acids and fermented ingredients. Food manufacturers accounted for 23.0% of end-user revenue and are expected to grow at a 6.03% CAGR. End-user demand is reinforced by large-scale beverage and ingredient producers such as global breweries, dairy processors, and probiotic manufacturers that rely on controlled fermentation for consistent product quality and high-volume output.

Stainless-steel systems remain dominant in breweries and high-volume ingredient plants. Smaller modular systems are gaining use in specialty cultures, pilot plants and fermented-protein development.

Industrial biotechnology generated USD 0.5032 billion in 2025, equal to 17.0% of the market. Revenue is projected to reach USD 1.0260 billion by 2032, expanding at a 10.71% CAGR. Demand is supported by bio-based chemical producers, enzyme manufacturers, and alternative protein developers that use fermentation platforms for scalable production of industrial inputs and next-generation food ingredients.

 

Automation Increases Revenue Beyond the Fermenter Vessel

Fermenters are increasingly sold as integrated production systems rather than stand-alone tanks. Customers require automated feeding, gas-flow control, electronic batch records, process monitoring and remote diagnostics. Major equipment companies are expanding their bioprocessing portfolios. For example, Danaher disclosed more than USD 2 billion in investment across bioprocessing capacity, digital capabilities and regional manufacturing. Thermo Fisher introduced a 5-liter DynaDrive bioreactor to connect development work with larger manufacturing systems. Sartorius reported €2.865 billion in 2025 Bioprocess Solutions revenue, with constant-currency growth of 9.5%.

 

Asia-Pacific Moves Toward Regional Leadership

North America led the market with 32.0% of 2025 revenue, equal to USD 0.9472 billion. The regional market is forecast to reach USD 1.7100 billion by 2032, growing at an 8.81% CAGR. North America benefits from a large biotechnology sector, established contract-manufacturing networks and continued investment in biologics production. The acquisition of Lonza’s Vacaville facility reflects demand for immediately available large-scale capacity. Key end-users include major biopharma and CDMO players such as Amgen, Pfizer, Moderna, and Lonza, which continue to expand fermentation-based biologics and vaccine production capacity.

Asia-Pacific accounted for 31.0% of 2025 revenue, or USD 0.9176 billion. It is the fastest-growing region at a 12.62% CAGR and is forecast to reach USD 2.1090 billion by 2032. Growth is concentrated in South Korea, China, India and other manufacturing centers. Samsung Biologics is expanding large-scale capacity in South Korea. Chinese contract manufacturers are adding single-use production lines. India’s BioE3 policy promotes biomanufacturing infrastructure and biofoundry development. Key end-users include Samsung Biologics, WuXi Biologics, Biocon, and SK bioscience, reflecting strong expansion in both contract manufacturing and domestic biopharma production.

Europe held 27.0% of 2025 revenue, equal to USD 0.7992 billion. It is projected to reach USD 1.3680 billion by 2032, expanding at a 7.98% CAGR, supported by demand from biopharmaceutical and food manufacturers such as Roche, Novartis, Sanofi, Bayer and GSK.

Latin America represented 5.0% of 2025 revenue and is forecast to grow at a 9.81% CAGR. Expansion is linked to food processing, beverages and regional pharmaceutical production. The Middle East and Africa also accounted for 5.0% of 2025 revenue. The region is projected to grow at a 6.37% CAGR, reflecting fewer major fermentation clusters and greater reliance on imported equipment.

 

Market Competition Shifts Toward Integrated Platforms

Competition includes bioprocess specialists, diversified life-science companies and food-processing engineering groups. Sartorius, Cytiva and Thermo Fisher compete through single-use systems, automation, consumables and scale continuity.

Stainless-steel equipment companies compete through vessel engineering, cleaning systems, utility integration and project execution. GEA reported 15 major contracts valued at a combined €560.6 million in 2025 across its broader processing portfolio. These awards show the scale available to companies that can deliver complete processing lines.

The main forecast risk is the gap between announced capacity and operational capacity. Projects may be delayed by construction problems, automation integration, qualification work, limited skilled labor or downstream bottlenecks.

Single-use systems also face concerns related to film integrity, extractables, leachables and waste. Stainless-steel facilities require high capital spending, water, steam and cleaning infrastructure.

The projected 9.8% market CAGR therefore depends on facilities moving from announcement to commissioning and routine production. Companies with proven scale-up performance, regional technical teams, dependable component availability and strong project execution are likely to gain market share.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.96 Billion
Revenue Forecast in 2032	USD 5.70 Billion
Overall Growth Rate	CAGR of 9.8% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
By Type	Stainless-Steel Fermenters; Single-Use Fermenters
By Application	Biopharmaceuticals; Food & Beverage; Industrial Biotechnology; Research
By End User	Biotech & Pharma Companies; CDMOs; Food Manufacturers; Academic Institutions
By Geography	North America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Market Drivers – Expansion of Biopharmaceutical Manufacturing	Rising production of monoclonal antibodies, recombinant proteins, vaccines, biosimilars, and other biologics is increasing demand for advanced fermentation systems across development and commercial manufacturing.
Market Drivers – Growth of Flexible Biomanufacturing Capacity	Increasing adoption of CDMO models and demand for multiproduct manufacturing facilities are accelerating the use of modular and single-use fermenters.
Market Drivers – Rising Demand for Fermented Products and Industrial Biotechnology	Growth in probiotics, functional foods, enzymes, biofuels, bioplastics, and alternative proteins is expanding fermentation equipment demand beyond pharmaceutical applications.
Customization Option	Available upon request